CN104163443A - Preparation method of Almagate serving as antiacid - Google Patents
Preparation method of Almagate serving as antiacid Download PDFInfo
- Publication number
- CN104163443A CN104163443A CN201310185675.3A CN201310185675A CN104163443A CN 104163443 A CN104163443 A CN 104163443A CN 201310185675 A CN201310185675 A CN 201310185675A CN 104163443 A CN104163443 A CN 104163443A
- Authority
- CN
- China
- Prior art keywords
- almagate
- salt
- preparation
- magnesium
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of Almagate serving as an antiacid. The molecular formula of the Almagate can be shown as Al2Mg6(OH)14(CO3)2.4H2O, and a tetradecahydroxy dialuminum hexamagnesium double salt hydrate is taken as an effective component of a medicament. The compound is prepared by performing a double decomposition reaction on a soluble aluminum salt or hydrates thereof (aluminum chloride and aluminum nitrate), a magnesium salt or hydrates thereof (magnesium chloride and magnesium nitrate) and carbonates (potassium carbonate and sodium carbonate) in water under a heating condition. The medicament can be taken as a very ideal treatment medicament for resisting stomach acid.
Description
The present invention relates to the preparation method of antacid almagate, the molecular formula of this antacid almagate is as follows:
Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Gastroenteropathy is one of common disease of very easily suffering from of human body, and due to its easy sick sending out, sufferer kind is more and be difficult to radical cure, has greatly damaged people's physical and mental health, is divided into following several in the market for the common medicine of gastroenteropathy treatment:
1, in and hydrochloric acid in gastric juice medicine class mainly contain tri-kinds of roter tablets, bismuth potassium citrate and Di Le, for gastric and duodenal ulcer, the patient of gastritis and hyperchlorhydria
2, gastric acid inhibitory medicine class is taking H2 receptor blocking agent as main, and conventional at present have Ranitidine HCL, famotidine and safe stomach U.S., a cimitidine.These medicines are mainly used in treating duodenal ulcer, postoperative ulcer, benign gastric ulcer, reflux esophagitis, upper gastrointestinal hemorrhage.
3, mucous membrane protection class mainly contains bismuth aluminate compound.Primary treatment Peptic Ulcers, hyperchlorhydria, gastritis, nervous indigestion, gastrointestinal spasm etc.In addition, go back adjustable gastric intestinal tympanites, improve constipation, improve a poor appetite and improve digestive function.
4, medicine for stomach dynamic class has motilium, stomach clothes peace, not husky Billy.Can increase esophagus hypomere sphincter tone, strengthen peristole, promote stomach emptying, coordinate stomach and uodenal movement, prevent bile reflux, regulate and recovery gastrointestinal motility.
Antacid almagate, there is larger surface-area, give its good antiacid effect, every gram of consumption 28.3 milliequivalent hydrochloric acid, according to external antiacid experimental result, fast 4 times than aluminium hydroxide of speed of actions, strong 8 times, faster with regard to sour agent speed of action than other, it is also long that the interior pH of stomach maintains the 3-5 time, there is no hydrochloric acid in gastric juice bounce-back.Almagate is that a kind of neutralizing effect is rapid, and neutralising capacity is powerful, and effect is lasting, anacidity rebound phenomena, and absorption cholic acid, relieving haperacidity activity does not reduce with digestive ferment (particularly stomach en-) effect, and side effect is little, safe novel antacid.This medicine has vast development prospect aspect peptic ulcer (PU) prevention and treatment.
The object of this invention is to provide a kind of preparation method of antacid almagate.This reaction scheme raw material is cheap and easy to get, and technological operation is easy, and constant product quality is controlled, is applicable to suitability for industrialized production.
The preparation of almagate utilizes the method for metathesis hydration in chemistry synthetic, wherein a kind of the most effective method is to utilize the aluminium salt of solubility, the carbonate of solubility and the magnesium salts of solubility are raw material, carry out metathesis hydration reaction and generate almagate in the aqueous solution, and typical chemical equation is:
2AlCl
3·nH
2O+6MgCl
2·nH
2O+9Na
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Similarly aluminum soluble salt can be aluminum chloride or its hydrate, aluminum nitrate, preferably aluminum chloride or its hydrate.Carbonate is sodium carbonate, preferably sodium carbonate.Magnesium salts is magnesium nitrate or magnesium chloride or its hydrate, the general preferred magnesium chloride of magnesium salts or its hydrate.
Concentration for various salts solutions is chosen in 10-50%, the general preferred 10-25% of aluminium salt, more preferably 17%.The general preferred 15-28% of carbonate, more preferably 21%.The general preferred 20-31% of magnesium salts, more preferably 26%.In the aqueous solution, react, temperature of reaction is 80-110 DEG C, preferably 90-100 DEG C.Time for adding is 1-4 hour, preferably 2-3 hour.Reaction times is 0.4-1 hour, preferably 0.5 hour.
Embodiment
Embodiment mono-:
2AlCl
3·6H
2O+6MgCl
2·6H
2O+9Na
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Get Aluminum Chloride Hexahydrate 48.28g, magnesium chloride hexahydrate 122g, is jointly dissolved in 400ml pure water and is made into the mixed salt aqueous solution, gets sodium carbonate 94.4g and is dissolved in 500ml pure water and is made into aqueous sodium carbonate.Then use volume pump by mixed salt solution and aqueous sodium carbonate being added dropwise to and being heated in 95 DEG C of reaction flasks that fill 400ml pure water at the uniform velocity simultaneously.After dripping, reaction reaches terminal, and by resultant and reaction solution, heated and stirred at 95 DEG C is processed 0.5 hour, be cooled to 50 DEG C, filter liquor obtains solid sediment, 800ml pure water water washing under room temperature, and at 100 DEG C, dry and within 4 hours, be product, yield 98%.
Embodiment bis-:
2AlCl
3·6H
2O+6MgCl
2·6H
2O+9Na
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Get Aluminum Chloride Hexahydrate 24.14Kg, magnesium chloride hexahydrate 61Kg, is jointly dissolved in 200L pure water and is made into the mixed salt aqueous solution, gets sodium carbonate 47.2Kg and is dissolved in 250L pure water and is made into aqueous sodium carbonate.Then use volume pump by mixed salt solution and aqueous sodium carbonate being added dropwise to and being heated in 95 DEG C of reaction flasks that fill 200L pure water at the uniform velocity simultaneously.After dripping, reaction reaches terminal, and by resultant and reaction solution, heated and stirred at 95 DEG C is processed 0.5 hour, be cooled to 50 DEG C, filter liquor obtains solid sediment, 400L pure water water washing under room temperature, and at 100 DEG C, dry and within 4 hours, be product, yield 98.5%.Embodiment tri-:
2AlCl
3·6H
2O+6MgCl
2·6H
2O+9K
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Get Aluminum Chloride Hexahydrate 48.28g, magnesium chloride hexahydrate 122g, is jointly dissolved in 400ml pure water and is made into the mixed salt aqueous solution, gets salt of wormwood 124.2g and is dissolved in 500ml pure water and is made into wet chemical.Then use volume pump by mixed salt solution and aqueous sodium carbonate being added dropwise to and being heated in 95 DEG C of reaction flasks that fill 400ml pure water at the uniform velocity simultaneously.After dripping, reaction reaches terminal, and by resultant and reaction solution, heated and stirred at 95 DEG C is processed 0.5 hour, be cooled to 50 DEG C, filter liquor obtains solid sediment, 800ml pure water water washing under room temperature, and at 100 DEG C, dry and within 4 hours, be product, yield 97.5%.Embodiment tetra-:
2Al(NO
3)
3·9H
2O+6Mg(NO
3)
2·6H
2O+9Na
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Get nine water aluminum nitrate 75g, magnesium nitrate hexahydrate magnesium 153.8g, is jointly dissolved in 400ml pure water and is made into the mixed salt aqueous solution, gets sodium carbonate 94.4g and is dissolved in 500ml pure water and is made into aqueous sodium carbonate.Then use volume pump by mixed salt solution and aqueous sodium carbonate being added dropwise to and being heated in 95 DEG C of reaction flasks that fill 400ml pure water at the uniform velocity simultaneously.After dripping, reaction reaches terminal, and by resultant and reaction solution, heated and stirred at 95 DEG C is processed 0.5 hour, be cooled to 50 DEG C, filter liquor obtains solid sediment, 800ml pure water water washing under room temperature, and at 100 DEG C, dry and within 4 hours, be product, yield 96%.Embodiment five:
2Al(NO
3)
3·9H
2O+6Mg(NO
3)
2·6H
2O+9K
2CO
3+H
2O→Al
2Mg
6(OH)
14(CO
3)
2·4H
2O
Get nine water aluminum nitrate 75g, magnesium nitrate hexahydrate magnesium 153.8g, is jointly dissolved in 400ml pure water and is made into the mixed salt aqueous solution, gets salt of wormwood 124.2g and is dissolved in 500ml pure water and is made into wet chemical.Then use volume pump by mixed salt solution and aqueous sodium carbonate being added dropwise to and being heated in 95 DEG C of reaction flasks that fill 400ml pure water at the uniform velocity simultaneously.After dripping, reaction reaches terminal, and by resultant and reaction solution, heated and stirred at 95 DEG C is processed 0.5 hour, be cooled to 50 DEG C, filter liquor obtains solid sediment, 800ml pure water water washing under room temperature, and at 100 DEG C, dry and within 4 hours, be product, yield 95%.
Claims (5)
1. a preparation method for gastric antiacids thing almagate, the molecular formula of almagate is as follows:
Al
2Mg
6(OH)
14(CO
3)·4H
2O
2. according to a preparation method for medicine described in claim 1, it is characterized in that utilizing aluminum soluble salt or its hydrate, soluble carbonate salt, solubility magnesium salts or its hydrate react and generate almagate in the aqueous solution, and its chemical equation is:
2Al
3++6Mg
2++9CO
3 2-+11H
2O→Al
2Mg
6(OH)
14(CO
3)·4H
2O
3. according to preparation method claimed in claim 2, it is characterized in that solvable new aluminium salt is nitrate, muriate.Carbonate is salt of wormwood, sodium carbonate.Magnesium salts is nitrate, muriate.
4. according to the preparation method under claim 3, preferably aluminium salt is aluminum chloride or its hydrate, and preferably magnesium salts is magnesium chloride or its hydrate.
5. according to the preparation method under claim 3, preferably carbonate is sodium carbonate or salt of wormwood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310185675.3A CN104163443A (en) | 2013-05-20 | 2013-05-20 | Preparation method of Almagate serving as antiacid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310185675.3A CN104163443A (en) | 2013-05-20 | 2013-05-20 | Preparation method of Almagate serving as antiacid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104163443A true CN104163443A (en) | 2014-11-26 |
Family
ID=51907452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310185675.3A Pending CN104163443A (en) | 2013-05-20 | 2013-05-20 | Preparation method of Almagate serving as antiacid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104163443A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105911057A (en) * | 2016-06-22 | 2016-08-31 | 扬州洋制药有限公司 | Quality control method of almagate suspension |
| CN106074596A (en) * | 2016-06-22 | 2016-11-09 | 扬州洋制药有限公司 | A kind of suspendible method of almagate |
| CN108159072A (en) * | 2017-12-04 | 2018-06-15 | 上海裕英生物医药科技有限公司 | The preparation process of almagate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1605345A (en) * | 2003-10-07 | 2005-04-13 | 查红梅 | Medicine for stomach disease |
-
2013
- 2013-05-20 CN CN201310185675.3A patent/CN104163443A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1605345A (en) * | 2003-10-07 | 2005-04-13 | 查红梅 | Medicine for stomach disease |
Non-Patent Citations (2)
| Title |
|---|
| 杨波等: "铝镁加的合成", 《沈阳药科大学学报》 * |
| 王国清等: "镁加铝的合成及稳定性研究", 《沈阳药科大学学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105911057A (en) * | 2016-06-22 | 2016-08-31 | 扬州洋制药有限公司 | Quality control method of almagate suspension |
| CN106074596A (en) * | 2016-06-22 | 2016-11-09 | 扬州洋制药有限公司 | A kind of suspendible method of almagate |
| CN105911057B (en) * | 2016-06-22 | 2018-10-19 | 扬州一洋制药有限公司 | A kind of method of quality control of almagate suspension |
| CN106074596B (en) * | 2016-06-22 | 2018-10-19 | 扬州一洋制药有限公司 | A kind of suspension method of almagate |
| CN108159072A (en) * | 2017-12-04 | 2018-06-15 | 上海裕英生物医药科技有限公司 | The preparation process of almagate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3650704A (en) | Novel synthetic hydrotalcite and antacid comprising said synthetic hydrotalcite | |
| CN104837503B (en) | Treating the Compounds and methods for that the antiport in relevant disease and enterogastric diseases being used to that NHE- to be inhibited to mediate is overloaded with fluid retention or salinity | |
| CN104163443A (en) | Preparation method of Almagate serving as antiacid | |
| RU2017117413A (en) | CARBIDOPA AND L-DOPA MEDICINES AND THEIR APPLICATION FOR TREATMENT OF PARKINSON'S DISEASE | |
| TWI742004B (en) | Extended use zirconium silicate compositions and methods of use thereof | |
| CN102775340A (en) | Method for synthesizing pyroglutamic calcium glutamate with shells serving as calcium sources | |
| JP2010534643A5 (en) | ||
| US2958626A (en) | Basic aluminum magnesium carbonate | |
| CN107416872A (en) | The preparation method of magnalium carbonate form hydrotalcite | |
| CN102140092A (en) | Hydrate of ilaprazole salt, preparation method thereof and application thereof | |
| CN104402706A (en) | Preparation method of high-purity calcium citrate | |
| TWI477294B (en) | Use for magnesium oxide particle | |
| JP2009500358A5 (en) | ||
| CN108078937B (en) | Hydrotalcite tablet and preparation method thereof | |
| CN104000628B (en) | Stomach first aid capsule haemostat and Hemostasis | |
| CN109809454B (en) | Purification process of colloidal compound | |
| US1542006A (en) | Decolorizing carbon particularly for medicinal use | |
| WO2005067975A1 (en) | Title: a sustained release captopril formulation having a supermolecular intercalation structure and the preparation process thereof | |
| US3300277A (en) | Hydrated magnesium aluminate and process for preparing same | |
| CN102150685B (en) | Binary magnesium-aluminum hydrotalcite and use thereof as disinfectant | |
| WO2018229789A1 (en) | An inorganic base antacid compound with improved and novel properties | |
| US10517893B2 (en) | Cationic binder, pharmaceutical composition comprising the same and method of using the same | |
| RU2442593C2 (en) | Method for bischofite purification | |
| CN1927220B (en) | Montmorillonite gelling preparation for treating diarrhea and gastritis and its preparation process | |
| CN108276340A (en) | Produce the synthetic method of metronidazole API |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING MINGZE ZHONGHE DRUG RESEARCH CO., LTD. Free format text: FORMER OWNER: BEIJING HECHENGXIANFENG MEDTEC CO., LTD. Effective date: 20150113 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150113 Address after: 102629, Beijing, Zhongguancun Daxing District science and Technology Park, Daxing pharmaceutical industry base, No. 25 Yongxing Road, room 1, C3F08 Applicant after: BEIJING MINGZE ZHONGHE MEDICAMENT RESEARCH CO., LTD. Address before: 102629 Beijing biological medicine base, road, room 25, Yongxing Road, Beijing, Daxing District Applicant before: Beijing Hecheng Xianfeng Pharmaceutical Technology Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141126 |
|
| RJ01 | Rejection of invention patent application after publication |